ERBB2 and gastric cancer: According to the phase II NEOHX study (8) and HER-FLOT study (9), trastuzumab can be safely added to neoadjuvant chemotherapy, and this combination approach resulted in pCR rates ranging from 8.3% to 22.2% in patients with locally advanced HER2-positive GC.